Eli Lilly and Company (LLY)

Market Cap	865.51B
Revenue (ttm)	59.42B
Net Income (ttm)	18.41B
Shares Out	895.38M
EPS (ttm)	20.44
PE Ratio	47.29
Forward PE	32.18
Dividend	$6.00 (0.62%)
Ex-Dividend Date	Nov 14, 2025

Volume	5,696,640
Open	939.74
Previous Close	924.37
Day's Range	938.41 - 981.99
52-Week Range	623.78 - 981.99
Beta	0.39
Analysts	Strong Buy
Price Target	993.12 (+2.74%)
Earnings Date	Oct 30, 2025

About LLY

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1876
• Employees: 47,000
• Stock Exchange: NYSE
• Ticker Symbol: LLY
• Website: https://www.lilly.com

Financial Performance

In 2024, Eli Lilly's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Analyst Summary

According to 17 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price target is $993.12, which is an increase of 2.74% from the latest price.

Price Target

$993.12

(2.74% upside)

Analyst Consensus: Strong Buy